Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

John T. Leith; Shaker A. Mousa; Aleck Hercbergs; Hung-Yun Lin; Paul J. Davis

doi:10.18632/oncotarget.26434

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

John T. Leith, Shaker A. Mousa, Aleck Hercbergs, Hung-Yun Lin and Paul J. Davis _

PDF | HTML | How to cite

Oncotarget. 2018; 9:37069-37075. https://doi.org/10.18632/oncotarget.26434

Metrics: PDF 1413 views | HTML 2145 views | ?

Abstract

John T. Leith1, Shaker A. Mousa2, Aleck Hercbergs3, Hung-Yun Lin4,5,6,7 and Paul J. Davis2,8

1Rhode Island Nuclear Science Center, Narragansett, RI, USA

2Pharmaceutical Research Institute, Albany College of Pharmacy and Health Sciences, Rensselaer, NY, USA

3Department of Radiation Oncology, Cleveland Clinic, Cleveland, OH, USA

4Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan

5PhD Program for Cancer Molecular Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan

6Traditional Herbal Medicine Research Center, Taipei Medical University, Taipei, Taiwan

7TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan

8Department of Medicine, Albany Medical College, Albany, NY, USA

Correspondence to:

Paul J. Davis, email: [email protected]

Keywords: integrin open configuration; AKT; epithelial-mesenchymal transition (EMT); L-thyroxine (T₄); STAT3

Received: August 30, 2018 Accepted: November 16, 2018 Published: December 11, 2018

ABSTRACT

Radioresistance is a substantial barrier to success in cancer management. A number of molecular mechanisms support radioresistance. We have shown experimentally that the thyroid hormone analogue receptor on the extracellular domain of integrin αvβ3 may modulate the state of radiosensitivity of tumor cells. Specifically, tetraiodothyroacetic acid (tetrac), a derivative of L-thyroxine (T₄), can reduce radioresistance in cancer cells. In this review, we list a number of intrinsic signal transduction molecules and other host factors that have been reported to support/induce radioresistance in cancer cells and that are also subject to control by T₄ through actions primarily initiated at integrin αvβ3. Additional preclinical evidence is needed to support these radioresistance-relevant actions of thyroid hormone.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26434

Publication Alerts

Reviews:

Radioresistance of cancer cells, integrin αvβ3 and thyroid hormone

Abstract